• About STARmed
  • Product
  • Clinical Info
  • News & Resources
  • Contact us

Choose a move location

You are leaving the STARmed United States site.

You just clicked a link to go to another STARmed website.
It is possible that some of the products on the other site are not approved in your region or country.

Seclect Your Region

Go to STARmed United States website.

The content of the United States website is related to the product information of the local region
and may be different from the product and the approval conditions of Korea.
This is not subject to domestic laws and regulations for the protection of Korean consumers.
In addition, all information given from this website with regards to the product and
usage of the product is for Licensed Medical Professionals.



스타메드의 미국 웹사이트로 이동합니다.

미국 웹사이트의 내용은 해당 지역의 제품 정보에 관한 것으로
국내 제품과는 품목 및 허가사항이 다를 수 있으며, 이는 국내 소비자의 보호를 위한
국내법 상의 광고 심의 규제를 받지 않습니다.
스타메드 웹사이트의 모든 정보는 전문 의료진을 위해 제공하는 제품과 사용법에 대한 정보임을 밝힙니다.

News

News Release

News Release

  • VENISTAR TODAY

  • Published by STARmed|March 24

  • added 10 new photo

1,400+
CONFIRMED CLINICAL CASES
Despite of COVID-19 outbreak, VENISTAR has successfully treated nearly 1,500 patients in the first year of launching in Korea.
Radiofrequency ablation (RFA) technology was first introduced for the treatment of saphenous veins or venous insufficiency in 1999. Today,

 
View this email in your browser
VENISTAR TODAY - NEWSLETTER
THE LATEST ENDOVENOUS RFA TECHNOLOGY

Radiofrequency ablation (RFA) technology was first introduced for the treatment of saphenous veins or venous insufficiency in 1999. Today, it is used as a standard treatment option for patients across the globe. Numerous international studies have proven both the safety of this technology as well as the increased QoL in patients following treatment. One of the main advantages of endovenous RFA is that it can be performed in an outpatient setting without the requirement of hospital admission or general anesthesia. The latest endovenous RFA device, VENISTAR has successfully treated nearly 1,500 patients in the first year of launching in Korea. With the Impedance controlled (IC) mode, it maximizes the benefit of RFA and QoL of patients.1


The latest endovenous RFA device, VENISTAR has successfully treated nearly 1,500 patients in the first year of launching in Korea. With the Impedance controlled (IC) mode, it maximizes the benefit of RFA and QoL of patients.
1,400+
CONFIRMED
CLINICAL CASES


Despite of COVID-19 outbreak, VENISTAR has successfully treated nearly 1,500 patients in the first year of launching in Korea.
IC (Impedance conotrolled) RFA

VENISTAR, unlike other endovenous RFA devices on the market, uses an impedance algorithm to maximize the energy and time that each vein is treated. Other endovenous RFA devices use a standardized temperature and time that do not take each vein size into consideration. VENISTAR automatically turns off after the impedance reaches a target value that correlates to each individual vein.
Q. How do we know the works properly?

A: We all are living in the era of Youtube, so seeing is believing! Please check the test video (with Phantom)  [here]. For more detailed and professional data, feel free to contact GM Kim (GM.Kim@STARmed4u.com).
“IC-RFA of VENISTAR showed outstanding 3-month results
for the treatment of incompetent saphenous veins
with no nerve injury or DVT.”
– Insoo Park MD, (2020 Korean Society for Phlebology)

STARmed is a leading manufacturer of radiofrequency technology for a variety of clinical applications. More than 300 clinical papers are published cited with STARmed RFA products.

MAXIMIZE RESULTS & SIMPLIFY PROCEDURES

By using internal cooling, VENISTAR keeps the temperature of the electrode less than 70° C compared to other endovenous RFA devices that ablate at a set 120° C. In addition to the already low complication rate of endovenous RFA2, VENISTAR’s internal cooling is expected to lower the possibility of heat injury. With VENISTAR, doctors can feel comfortable knowing that procedures are simplified with the automatic setting of IC-Mode.


STARmed – ALL ABOUT RFA

STARmed is a young and fast-growing company from South Korea, specializing in radiofrequency technology. Passionately working on the best possible RF treatment, STARmed has collaborated with a number of Key Opinion Leaders in developing the most innovative electrodes and leading-edge RF technology for a variety of clinical applications. STARmed is now recognized as the global leader in Thyroid RFA, and eagerly seeking global partnership with many researchers, as well as competitive distributors.
CONTACT INFORMATION

GM Kim

T: +82 31 816 3546 (Ext. 615)
M: +82 10 3335 4769
GM.Kim@STARmed4u.com
www.STARmed4u.com
PARTNERS WANTED – DOCTORS & DISTRIBUTORS

With a successful launch in Korea, STARmed is now looking for global collaboration. We are passionate and excited to offer distribution opportunities to company’s looking to expand their current product offering within the vascular space. Please contact us for more information.
1Ahmed Kayssi, et al. Endovenous radiofrequency ablation for the treatment of varicose veins. Can J Surg. 2015 Apr; 58(2): 85–86. (doi: 10.1503/cjs.014914)

2Alessandra Puggioni, et al. Endovenous laser therapy and radiofrequency ablation of the great saphenous vein: analysis of early efficacy and complications. J Vasc Surg . 2005 Sep;42(3):488-93. doi: 10.1016/j.jvs.2005.05.014.
STARmed Co., Ltd.
14F Daebang Triplaon, 158, Haneulmaeul-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, South Korea, 10355
This is a newsletter produced in collaboration with the VENISTAR Team and Marketing Team.
Facebook
Website
YouTube
Instagram
Linkedin